Unrelated Umbilical Cord Blood (UBC)Transplantation

Related Clinical Trial
Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia Long Term Follow-up Observational Study After Clinical Trials of AMG531 (Romiplostim) in Patients With Untreated Aplastic Anemia Efficacy and Safety of Lower-dose Decitabine in Refractory Aplastic Anemia Quantitative MRI of Bone Marrow Fat Fraction in Patients With Trepanobiopsy Avatrombopag Usage in NSAA Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization Retrospective Study of Patients With Severe Aplastic Anemia Who Relapsed After Immunosuppressive Therapy Retrospective Study of Patients With Severe Aplastic Anemia Who Developed High Risk Clonal Evolution With Chromosome 7Abnormalities After Immunosuppressive Therapy REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Investigation of the Cylex® ImmuKnow® Assay Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant Umbilical Cord Blood Transplantation From Unrelated Donors Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study Unrelated Umbilical Cord Blood (UBC)Transplantation New York Blood Center National Cord Blood Program Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis Effects of Aerobic Training and Inspiratory Muscle Training in Patients During Hematopoietic Stem Cell Transplantation A Phase II Study of Umbilical Cord Blood Transplantation Transplants With Unlicensed Preserved Cord Blood Safety Study of Cord Blood Units for Stem Cell Transplants Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells Trial of Two Central Venous Catheter (CVC) Flushing Schemes in Pediatric Hematology and Oncology Patients Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias. Protection Against Benzene Toxicity Treatment of Menorrhagia in Women With Thrombocytopenia Using Platelets or Platelets and Hormones Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAA Etiology of Blood Dyscrasias: Analysis of the International Agranulocytosis and Aplastic Anemia Study Data Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders King’s Invasive Aspergillosis Study II Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy Aplastic Anemia Epidemiology: Incidence and Case-control Drug Etiology of Aplastic Anemia and Related Dyscrasias hATG+CsA vs hATG+CsA+Eltrombopag for SAA Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia Conditioning Regimens for Patients With Severe Aplastic Anemia Transplanted With Marrow From an Unrelated Donor Study of Allogeneic Bone Marrow and T-Cell Depleted, CD34+ Peripheral Blood Stem Cell Transplantation in Patients With Aplastic Anemia Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients Efficacy and Safety of Thrombopoietin In Patients With Severe and Very Severe Aplastic Anemia Study of MRI Monitoring in Patients With Aplastic Anemia and Low or Int-1 Risk of MDS Complicated With Iron Overload A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia Flu+CPM+rATG Conditioning Regimes for Unrelated Bone Marrow Transplantation (UBMT)(or Mobilized Peripheral Blood)in Severe Aplastic Anemia (SAA) Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Severe Aplastic Anemia Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome Efficacy and Safety of Eltrombopag + CSA in Patients With Moderate Aplastic Anemia (EMAA) Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia Multi Center Case Control Study on Multiple Risk Factors of Aplastic Anemia NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment Safety and Efficacy Study of Ex Vivo Immunotherapy for Treatment of Aplastic Anemia Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA) Haploidentical Transplantation in Severe Aplastic Anemia A Description of Bacteria in the Mouths of Patients With Severe Aplastic Anemia Efficacy and Safety of Eltrombopag + Tacrolimus in Chinese Refractory or Relapsed Aplastic Anemia Patients A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia (SAA) Patient Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant Peripheral Blood Allogenic Stem Cell Transplantation Using Non-anti Thymocyte Globulin Regimens in Severe Aplastic Anemia Patients A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant Purified CD34+ Hematopoietic Stem Cell Transplantation From Alternate Donors for Patients With Severe Aplastic Anemia Stem Cell Factor Medication for Aplastic Anemia Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome Extended Dosing With Eltrombopag for Severe Aplastic Anemia Randomized Study In Severe Aplastic Anemia Patients Receiving Atg, Cyclosporin A, With Or Without G-CSF (SAA-G-CSF) Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Aplastic Anemia Stem Cell Mobilization Potential in Patients With Aplastic Anemia in Remission A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia Mycophenolate Mofetil and Cyclosporine to Treat Relapsing Aplastic Anemia Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Aplastic Anemia Collection of Blood and Bone Marrow From Patients With Aplastic Anemia for Analysis of Adhesion Molecules, Chemokines and Their Receptors Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia Alefacept in Patients With Relapsed/Refractory Aplastic Anemia Oral Manifestations of Aplastic Anemia The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia Clinical Study of Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole Mesenchymal Stem Cells Transplantation to Patients With Relapsed/Refractory Aplastic Anemia. Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia Neuropsychological Effects of Immunosuppressive Treatment in Subjects With Aplastic Anemia Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia Reduced Toxicity Fludarabine (Flu) + Cyclophosphamide (CPM) + Rabbit Antithymocyte Globulin (rATG) Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia (SAA) ATG Combined With Cyclophosphamide And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia A Novel TBI Free Conditioning Protocol for Haploidentical Transplant in Acquired Aplastic Anemia: Combination Therapy of Severe Aplastic Anemia Comparing Therapies for the Treatment of Severe Aplastic Anemia Mesenchymal Stem Cells Co-transplantation in Alternative Donor Transplantation of Severe Aplastic Anemia. Study of AMG531(Romiplostim) in Patients With Aplastic Anemia Bone Marrow Transplant Trial for Patients With Refractory Severe Aplastic Anemia Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia Improving Immunosuppressive Treatment for Patients With Severe Aplastic Anemia Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia Rabbit Antithymocyte Globulin (Thymoglobuline) With Ciclosporin for Patients With Acquired Aplastic Anaemia Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia A Study to Assess Efficacy and Safety of PF-06462700 in Japanese Participants With Aplastic Anemia Alemtuzumab and Rituximab in Aplastic Anemia Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia Comparison of Two Different Doses of Rabbit ATG-Fresenius With Cyclosporin in the Treatment of Acquired Aplastic Anaemia Mesenchymal Stem Cells in the Treatment of Relapsed/Refractory Severe Acquired Aplastic Anemia Study of Fludarabine + Cyclophosphamide + TBI Conditioning Regimen for Double Units Cord Blood Transplantation(CBT)in Severe Aplastic Anemia(SAA) Safety and Efficacy of Patient’s Own AD-MSC and AD-HSC Transplantation in Patients With Severe Aplastic Anemia Ambispective Observational Study to Evaluate the Incidence and Management of Aplastic Anemia in Spain Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia

Brief Title

Unrelated Umbilical Cord Blood (UBC)Transplantation

Official Title

Unrelated Umbilical Cord Blood (UCB) Transplantation

Brief Summary

      Hematopoietic progenitor cell (HPC- primitive cells in the blood, bone marrow and umbilical
      cord that can restore the bone marrow) transplant can be a curative therapy for the treatment
      of hematologic malignancies (a disease of the bone marrow and lymph nodes). The source of
      cells used for the transplant comes from related (sibling) and in cases where there is no
      sibling match, from unrelated donors through the National Marrow Donor Program. The
      availability of a suitable donor can be a significant obstacle for patients who need a
      transplant but do not have a matched donor. Cord blood that has been harvested from an
      umbilical cord shortly after birth has a rich supply of cells needed for transplant. These
      stored cord bloods are now being used to transplant adults without a matched donor

      Advantages to using cord blood includes a readily available source of cells with no risk to
      the donor during the collection process, immediate source of cells in urgent situations (no
      lengthy donor work-up)and a reduction in infectious disease transmission to the recipient.

      One of the main disadvantages is the cord blood has a small number of cells needed for
      transplant. In an adult, usually two cords are needed and large recipients do not qualify
      because they need too many cells.

      This study will use two different preparative regimens (chemotherapy and radiation) followed
      by one or two umbilical cord units (UBC). The preparative regimen used will be chosen by the
      physician and is based on patient's age, disease and medical condition at the time of

      Multiple objectives for this study include disease-free and overall survival, treatment
      related mortality, rate of cells taking hold, and the incidence and severity of the
      transplant complication called graft versus host disease (GVHD).

Detailed Description

      Allogeneic hematopoietic cell transplantation (allo- HCT) is a curative therapy for the
      treatment of hematological and non-hematological malignancies and certain non-malignant
      conditions. Bone marrow or peripheral blood from a Human Leukocyte Antigen (HLA) matched
      sibling donor is the most commonly used source of allogeneic stem cells. However, HLA matched
      siblings are available for less than one third of the patients who require allo-Stem Cell
      Transplant (allo-SCT). In the absence of an HLA matched sibling, volunteer unrelated donors
      or partially mismatched related donors (PMRD), stored cord blood may be used as a source of
      allogeneic stem cells. Stored cord blood has been used as a source of allogeneic stem cells
      in infants and children, but had early skepticism in adults because of concerns about the
      engraftment potential of the relatively limited number of stem cells. The number of stem
      cells in a unit of cord blood is generally one log less than the number of stem cells on an
      average collection of bone marrow from an adult for transplantation.

      After the success of the first allogeneic umbilical cord blood transplantation in 1988,
      programs for banking screened unrelated donor CBSC have been initiated both in the United
      States and Europe. Dr Pablo Rubenstein started the first such bank at the New York Blood
      Center (NYBC) in 1993. Since its inception, the NYBC has provided unrelated donor cord blood
      stem cells for over 1000 transplants. Analysis of outcomes for the initial 562 transplant
      recipients from the NYBC revealed a cumulative rate of engraftment of 81% by day 42 for PMNs.
      and 85% by day 180 for platelets. Currently, approximately more than 100,000 cord blood units
      are available in cord blood banks worldwide and more than 2000 patients have received cord
      blood transplants from these banks. NetCord, an international cooperative group of cord blood
      banks, has developed a detailed set of standards for cord blood banking to facilitate
      international exchanges and to guarantee the quality of these products.

      Cord Blood Unit Selection:

      UCB units will be required to be a 4 to 6 of 6 HLA-A, -B antigen and -DRB1 allele match with
      the patient. Typing at HLA-C and -DQ will be obtained but not required in the match strategy.
      A minimum total nucleated cell (TNC) dose of >2.0 x 107/kg at the time of freezing will be
      utilized when possible. When using double units, each unit should contain a minimum
      pre-cryopreserved TNC dose of 1.5 x 107/kg.

      UCB Transplant Procedure:

      There will be a myeloablative and reduced-intensity preparative regimen that can be given
      prior to infusion of cord product. The myeloablative approach will be selected in younger
      patients (<50yo) with a HCT-CI score <3. The reduced-intensity regimen will be selected for
      all older patients (>50) or younger patients with a hematopoietic cell
      transplantation-specific comorbidity index (HCT-CI) score >3. The reduced-intensity regimen
      will also be chosen for any patients being transplanted for indolent/follicular lymphomas,
      CLL, myeloma, or Hodgkin lymphoma; irrelevant of age or HCT-CI score. On a case by case
      basis, patients may receive a preparative regimen outside of their designated category as
      noted above with the approval of the PI, if deemed in the patient's best interest.

Study Type


Primary Outcome

Number of Participants With Engraftment

Secondary Outcome

 Overall Survival at Day 180 Post-transplant


Chronic Myelogenous Leukemia (CML)


umbilical cord blood (UCB)

Study Arms / Comparison Groups

Description:  After a preparative regimen the patient will receive an infusion of one or two umbilical cord blood unit(s) (UBC). The UBC unit(s) will be thawed according to methods of Rubinstein et al. If two products are used, they will be administered sequentially on the same day 1-6 hours apart. Tacrolimus and mycophenolate mofetil (MMF) will be used for GVHD prophylaxis. On day +30, +60, +100, +180, and +365 the chimeric status of patients will be interpreted by variable number tandem repeat (VNTR) analysis. Immune reconstitution (Digeorge Panel) will also be checked at these time points.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

February 3, 2009

Completion Date

April 6, 2021

Primary Completion Date

May 14, 2019

Eligibility Criteria

        Inclusion Criteria:

          -  Age: 16-70 years

          -  Available 4/6, 5/6, or 6/6 HLA antigen match (using A, B, and DRB1) cord blood unit.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (Karnofsky greater
             than or equal to 70%)

          -  Serum bilirubin less than 2 x upper limit of normal

          -  Serum creatinine less than 2 mg/dl

          -  DLCO or FEV1 greater than or equal to 50% predicted

          -  Left ventricular ejection fraction greater than or equal to 35%

          -  no uncontrolled infection

          -  If female, not pregnant

          -  Informed consent given

          -  No major organ dysfunction precluding transplantation.

          -  One of the following malignancies or bone marrow failure syndromes:

               -  Chronic myelogenous leukemia (CML)

               -  Acute myelogenous leukemia (AML)

               -  Myelodysplastic syndrome

               -  Multiple myeloma

               -  Hodgkin lymphoma

               -  Non-Hodgkin lymphoma

               -  Chronic lymphocytic leukemia (CLL)

               -  Acute lymphocytic leukemia (ALL)

               -  Severe Aplastic Anemia

        Exclusion Criteria:

          -  Patient pregnant

          -  Age less than 16, greater than 70

          -  ECOG performance status of greater than 2 (Karnofsky less than 70%)

          -  Psychiatric disorder or mental deficiency of the patient sufficiently severe as to
             make compliance with the BMT treatment unlikely, or making informed consent impossible

          -  Serum bilirubin greater than or equal to 2 x upper limit of normal, transaminases
             greater than 3 x upper limit of normal

          -  Serum creatinine greater than or equal to 2 mg/dl

          -  DLCO less than 50% predicted

          -  Left ventricular ejection fraction less than 35%

          -  Major anticipated illness or organ failure incompatible with survival from Bone Marrow
             Transplant (BMT)




16 Years - 70 Years

Accepts Healthy Volunteers



Michael Craig, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID

WVU 1909

Responsible Party


Study Sponsor

West Virginia University

Study Sponsor

Michael Craig, MD, Principal Investigator, West Virginia University

Verification Date

June 2021